Recent Advances in the Treatment and Management of Ovarian Cancer: Expert Perspectives on the Evolving Role of PARP Inhibitors

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2021 Fall Managed Care Forum.
If you participated in the live session, you are not eligible for continuing
education credits from this archive.

This activity is valid from January 1, 2022, to March 1, 2023.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
AstraZeneca, GlaxoSmithKline and Merck Sharp & Dohme Corp.

There will be an estimated 21,410 new cases of ovarian cancer this year in the United States, and an estimated 13,770 deaths due to ovarian cancer in the US, according to the American Cancer Society. Ovarian cancer is usually found late, stage 3 or higher, where it has already spread or metastasized to other parts of the abdomen, or worse. This is due in large part to a lack of symptoms during the earlier stages. The five-year survival rate is only 45%. Fortunately for patients with ovarian cancer, the treatment paradigm has exploded in the past three years, giving medical directors and clinicians more options in managing patients with ovarian cancer. Leading the way in new options for ovarian cancer are poly (ADP-ribose) polymerase (PARP) inhibitors, which have shown improved efficacy for patients with ovarian cancer. Additionally, new indications for these targeted agents offer expanded options in the maintenance setting in varying lines of therapy. This activity on the role of PARP inhibition therapies in the management of ovarian cancer will address this gap in knowledge by providing attendees with updated education on the selection of optimal testing strategies to personalize care, new options for first-line maintenance therapy, reviewing recent clinical data, managing treatment toxicities, the development of evidence-based sequencing and combination strategies, and managed care considerations for these options.

Upon completion of this activity, participants will be able to:

  • Examine the clinical and economic burden of ovarian cancer, including factors that contribute to poor prognosis and increased costs

  • Identify emerging trends in the clinical use of PARP inhibitors for the treatment of ovarian cancer

  • Compare and contrast safety and efficacy outcomes from recent pivotal trials on PARP inhibitors in ovarian cancer, with a close look at the maintenance setting

  • Examine how the recent trends in use of PARP inhibitors will impact the cost of caring for patients with ovarian cancer

  • Assess strategies for anticipating, recognizing, and managing adverse events of PARP inhibitor therapy in patients with ovarian cancer

  • Discuss the managed care considerations of PARP inhibitors by exploring where these agents fit in the ovarian cancer management paradigm


Faculty: Robert L. Coleman, MD, FACOG, FACS
Chief Scientific Officer, US Oncology Research
Co-Director, GOG-Partners
President, International Gynecologic Cancer Society


Dr. Coleman has served on an advisory board for AstraZeneca, Abbvie, Clovis, Roche/Genentech, Merck, GenMab, Immunogen, clovis, GSK, OncXerna, Deciphera, Novocure, Epsilogen, Agenus, Aravive Karyopharm, and Toray. He has received grant/research support from AstraZeneca, Abbvie, Clovis, GenMab, Immunogen, Merck, and Roche/Genentech. His presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
AstraZeneca, GlaxoSmithKline and Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue